To compare the efficacy of timolol maleate 0.5% vs fixed combination of timolol maleate 0.5%, and brimonidine tartrate 0.2% in control of raised intra ocular pressure in patients undergone Nd-Yag laser capsulotomy.
DOI:
https://doi.org/10.47672/ajhmn.933Keywords:
Nd-Yag laser, Timolol maleate 0.5%, Brimonidine Tartrate0.2%, Posterior capsular opacification.Abstract
Purpose: The purpose of the study is to compare the efficacy of Timolol maleate alone vs fixed combination of Timolol maleate 0.5% with Brimonidine 0.2% in patients undergone Nd-Yag laser capsulotomy.
Methodology: 100 patients with posterior capsular opacification were enrolled though OPD. They were placed in 2 groups with 50 patients each. Group A received Timolol maleate 0.5% alone while group B received combination of timolol maleate with Brimonidine tartrate.
Results: In group A 3 patients developed acute raise of intraocular pressure despite of Timolol maleate use while goup B patients who received combination of Timolo maleate and Brimonidine had controlled intraocular pressure.
Conclusion: Fixed combination of Timolo maleate 0.5% and Bremonidine tartrate 0.2 % is more effective in controlling of IOP raise in patients undergone Nd-Yag laser capsulotomy for posterior capsular opacification then Timolo maleate0.5% alone.
Downloads
References
Saeed MK, Ameen SS, Ibrahim MT. Frequency of raised IOP after Nd yag lasercapsulotomy. Professional Med J 2019; 16:410- 3.
BaigMsa, Ali MA. Yag laser capsulotomy. Review of 500 cases at civil hospital, Karachi. Pak J Surg 2019; 45(1):41-3.
Schauumberg DA, Dana MR. systemic overview of the incidence of Posterior Capsular Opacification. Ophthalmology 2019; 105: 1213-21.
Auttarth G. Ophthalmic epidemiology, oct 2020; 11(4) 319-29.
Kanski JJ. Clinical Ophthalmology, A systemic approach. 6th edition. Butterworth Heinmann. London 2020:P.358.
Pandy Sk, Apple D. Indian J Ophthalmol 2020; 52(2); 99-112.
Kashif M, Ansari U, Ahmad H. Pak J Ophthalmol 2019, vol. 25 no 4.
Arya SK, sonika S, Kumar. Malignant glaucoma as a complication of Nd yag laser posterior capsulotomy. Ophthalmic Surg laser imaging 2019; 35 vol (3) 248-50
Minello PP, Prata JA, Millo P. Efficacy of topical hypotensive agents after posterior capsulotomy. Arq Bras Oftalmol 2020; 71(5): 706-710.
Jahn CE, Richter J, Jahn AH. Post yag inflammatory raised iop. J Cataract Refracr Surg 2020; 29(5): 925-29.
Minello . Arq bras oftalmol sep – oct 2018.
Waseem M, Khan HA. Association of raised iop in its correlation to the energy used. J coll physians SUrg Pak 2010: 20: 524-7.
Saeed MK, Anum SS, Ibrahim MT. Raised iop frequency after Nd yag laser capsulotomy. Professional Med J 2019: 16: 410-3.
Oner v, Tas M. Brimonidine vs bremonidine plus timolol for treatment of raised iop after yag capsulotomy. J Ocul Pharmacol ther 2010:26:513-7.
Kanski JJ. Clinical Ophthalmology, A systemic approach. 6th edition. Butterworth Heinmann. London 2007:P.254.
Artunay O, Unal M, Rasyer R. Prevention of iop spike following Nd yag capsulotomy J Ocul Phamacol Ther 2010: 26: 513-7.
Niharika KS, Saridhar S. Variation in intraocular pressure spike following Nd-Yag laser capsulotomy. Indian J Ophthalmol 2016; 52(2); 99-112.
Channel MM, Beckmen H. IOP changes after Nd yag laser capsulotomy. Arch Ophthamol 2016; 102(7): 1024-26.
Nisher R, Colker AE. Failure of Timolol to prevent delayed IOP elevation after Nd yag capsulotomy. Trans Am Ophthalmol 2017; 88: 229-32.
Rakosky J, Coch DD. Efficacy of Timolol maleate 0.5% in raised IOP following Nd yag capsulotomy. Niger J Ophthalmol 2014; 22: 20-3.
Gartaganis SP, Mela EK, Katsimpres. Efficacy of 0.2% Brimonidine tartrate in controlling of IOP elevation following Nd yag laser capsulotomy. Ophthalmic Surg lasers. Sep-Oct 2017; 30(8): 647-52.
Seong GJ, Lee YG. Efficacy of Brimonidine 0.2% in patients undergone Nd yag posterior capsulotomy in patients with PCO. Ophthalmic Surg lasers July-Aug 2000;31(4); 308-14.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Ihsan Ullah, Muhammad Israr, Jehanzeb Khan, Mushtaq Khatak
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
